Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target connected Mirum Pharmaceuticals (MIRM) to $130 from $95 and keeps an Overweight standing connected the shares. Mirum’s projected acquisition of Bluejay Therapeutics for $250M successful cash, $300M successful stock, and $200M successful tiered milestone payments is simply a “steal,” the expert tells investors successful a probe note.

TipRanks Cyber Monday Sale

• Claim 60% disconnected TipRanks Premium for data-backed insights and probe tools you request to put with confidence.

• Subscribe to TipRanks' Smart Investor Picks and spot our information successful enactment done our high-performing exemplary portfolio - present besides 60% disconnected

Published archetypal connected TheFly – the eventual root for real-time, market-moving breaking fiscal news. Try Now>>

See the apical stocks recommended by analysts >>

Read More connected MIRM:

Disclaimer & DisclosureReport an Issue

• Mirum Pharmaceuticals Announces Merger with Bluejay Therapeutics

• Mirum Pharmaceuticals to get Bluejay Therapeutics successful cash, banal transaction

• Mirum Pharmaceuticals enrolls archetypal diligent successful Phase 2 BLOOM survey of MRM-3379

• Mirum Pharmaceuticals: Strategic Positioning and Strong Defense Justify Buy Rating

• Mirum Pharmaceuticals Faces Patent Challenge from Sandoz